Leo Pharma completes tralokinumab licensing deal with AstraZeneca

Leo Pharma has completed a licensing agreement with AstraZeneca that will provide the former with a global licence to the drug tralokinumab.

The firm has made a payment to AstraZeneca of $115 million (88.56 million pounds) for exclusive global rights to tralokinumab in atopic dermatitis and any future additional dermatology indications.

AstraZeneca will continue to retain a significant ongoing interest in tralokinumab, with this deal coming as part of a broader partnership between the two companies.

Tralokinumab is an IL-13 monoclonal antibody that has been assessed in phase IIb trials for the treatment of atopic dermatitis, an inflammatory skin disease characterised by itchy, red, swollen and cracked skin.

Gitte Aabo, president and chief executive officer of Leo Pharma, said: "By expanding our portfolio to include both biologics and topicals, Leo Pharma is set to become the world dermatology leader – offering the most diverse range of treatment solutions to meet the individual needs of people with skin diseases."

The company has also agreed to license the rights to the IL-17 receptor monoclonal antibody brodalumab from AstraZeneca as part of the same collaboration.

With? ?over? ?20? ?years? ?of? ?experience? ?within? ?the? ?pharmaceutical? ?market,? ?we? ?at? ?Zenopa? ?have? ?the knowledge,? ?skills? ?and? ?expertise? ?to? ?help? ?find? ?the? ?right? ?job? ?for? ?you.? ?To? ?find? ?out? ?more? ?about? ?the current? ?pharmaceutical? ?roles? ?we? ?have? ?available,? ?you? ?can? ?search? ?for? ?the? ?latest? ?job? ?roles, register? ?your? ?details,? ?or? ?contact? ?the? ?team? ?today.